Samsung Biologics has agreed to acquire 100% of Human Genome Sciences from GSK, a move that secures the company’s first U.S.-based biologics manufacturing site and reinforces its long-term commitment to the American biopharmaceutical supply chain. The Samsung Biologics HGS acquisition, carried out through its wholly owned subsidiary Samsung Biologics America, adds U.S. production capacity to complement the company’s established operations in Korea and strengthens resilience across its global manufacturing network as part of the Samsung Biologics U.S. manufacturing expansion.
The acquired facility is located in Rockville, Maryland, within one of the United States’ key biotechnology clusters. It includes two cGMP manufacturing plants with a combined 60,000 liters of drug substance capacity and supports both clinical and commercial production at small and large scales. Existing products will continue to be manufactured at the site, while Samsung Biologics plans further investments to expand capacity and upgrade technologies. These planned enhancements are intended to support growing manufacturing programs and reinforce the Samsung Biologics U.S. manufacturing expansion as part of a broader strategy to deliver flexible, multi-site manufacturing options to global clients.
Under the agreement, closing is anticipated toward the end of Q1 of 2026. Samsung Biologics will acquire the Rockville assets for USD 280 million and retain more than 500 employees at the site to maintain operational continuity and workforce stability. Once integrated into the company’s global network, the Maryland facility will give customers manufacturing options in both the U.S. and Korea, supporting the reliable supply of life-saving therapeutics for American patients as the Samsung Biologics U.S. manufacturing expansion continues through the Samsung Biologics HGS acquisition.
Samsung Biologics continues to scale its global operations following the on-time completion of Bio Campus I and II and the recent securing of land for Bio Campus III, which will house dedicated R&D and manufacturing programs for new modalities. Across five plants, the company operates 785,000 liters of capacity, positioning it as the industry leader in large-scale biologics manufacturing. Its portfolio spans monoclonal antibodies, antibody-drug conjugates (ADCs), mRNA, organoid-based services, and next-generation therapies.
“This landmark acquisition is a testament to our unwavering commitment to advancing global healthcare and bolstering our manufacturing capabilities in the U.S. The investment will enable us to deepen our collaboration with federal, state, and local stakeholders to best serve our customers and partners while ensuring a reliable and stable supply of life-saving therapeutics,” said John Rim, CEO and President of Samsung Biologics.
Regis Simard, President, Global Supply Chain at GSK, said, “Today’s agreement to divest the Rockville manufacturing site to our valued long-term partner, Samsung Biologics, will secure the manufacture of two important medicines on US soil for US patients and further build GSK’s supply chain resilience. Along with GSK’s recent commitment to invest $30bn in R&D and manufacturing in the US over the next 5 years, this deal enables us to further focus on building the agility, capacity and capability needed in our manufacturing network to deliver the next generation of specialty medicines and vaccines. I am confident in a positive partnership and future for the Rockville site.”
